2N Pharma’s ground-breaking approach to treating neurological diseases recognised in Nature Journal

2N Pharma’s founder and CSO and Assoc. Prof Dr. Nieland is proud that research performed in his Molecular Pharmacology group at Aalborg University is to be published today (30th April 2021) in the prestigious Nature Journal’s Communications Biology publication.

Our article “Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS” is the culmination of many years of academic research that underpins our development of new effective molecules to treat #ALS #MND #PD and #MS.

Assoc. Prof at Aalborg University and Co-Founder Dr. John Nieland says: “It’s been a long journey so far and there is still a long way to go, but we are on the path for a treatment that really works for many incurable diseases. This recognition of our work and its success to date, amongst our peers and the broader scientific community is a validation of our team’s dedication and commitment.”

Click here to read the article in full: